Geulah Livshits
Stock Analyst at Chardan Capital
(4.36)
# 342
Out of 5,154 analysts
252
Total ratings
46.83%
Success rate
20.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Buy | $26 → $27 | $13.44 | +100.89% | 19 | Mar 2, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $174 → $210 | $134.39 | +56.26% | 7 | Feb 24, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $220 → $323 | $253.69 | +27.32% | 15 | Feb 18, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $74 → $76 | $56.50 | +34.51% | 17 | Feb 17, 2026 | |
| LXEO Lexeo Therapeutics | Maintains: Buy | $17 | $6.85 | +148.18% | 14 | Jan 13, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $12 | $4.57 | +162.58% | 17 | Jan 6, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $26 | $8.48 | +206.60% | 14 | Dec 18, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $9 → $8 | $0.89 | +800.90% | 14 | Dec 12, 2025 | |
| SNTI Senti Biosciences | Maintains: Buy | $12 → $13 | $0.96 | +1,247.29% | 11 | Dec 9, 2025 | |
| IMTX Immatics | Maintains: Buy | $25 | $9.86 | +153.55% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $5.33 | +275.23% | 15 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $21 | $8.40 | +150.00% | 6 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $4.01 | +124.44% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $5.13 | +231.38% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 | $6.75 | +122.22% | 9 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $4.41 | +149.43% | 22 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $1.48 | +643.24% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $2.56 | +134.38% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.00 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $7.00 | +485.71% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $3.17 | +278.55% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $52.52 | +296.04% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $0.67 | +2,277.77% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $8.65 | +940.46% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.90 | +2.56% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $21.04 | -14.45% | 1 | Oct 27, 2020 |
Intellia Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $26 → $27
Current: $13.44
Upside: +100.89%
Palvella Therapeutics
Feb 24, 2026
Maintains: Buy
Price Target: $174 → $210
Current: $134.39
Upside: +56.26%
Krystal Biotech
Feb 18, 2026
Maintains: Buy
Price Target: $220 → $323
Current: $253.69
Upside: +27.32%
CRISPR Therapeutics AG
Feb 17, 2026
Maintains: Buy
Price Target: $74 → $76
Current: $56.50
Upside: +34.51%
Lexeo Therapeutics
Jan 13, 2026
Maintains: Buy
Price Target: $17
Current: $6.85
Upside: +148.18%
Taysha Gene Therapies
Jan 6, 2026
Maintains: Buy
Price Target: $12
Current: $4.57
Upside: +162.58%
4D Molecular Therapeutics
Dec 18, 2025
Maintains: Buy
Price Target: $26
Current: $8.48
Upside: +206.60%
Tenaya Therapeutics
Dec 12, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $0.89
Upside: +800.90%
Senti Biosciences
Dec 9, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $0.96
Upside: +1,247.29%
Immatics
Nov 24, 2025
Maintains: Buy
Price Target: $25
Current: $9.86
Upside: +153.55%
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $5.33
Upside: +275.23%
Nov 12, 2025
Maintains: Buy
Price Target: $6 → $21
Current: $8.40
Upside: +150.00%
Nov 10, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $4.01
Upside: +124.44%
Nov 6, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $5.13
Upside: +231.38%
Nov 4, 2025
Maintains: Buy
Price Target: $15
Current: $6.75
Upside: +122.22%
Oct 14, 2025
Maintains: Buy
Price Target: $11
Current: $4.41
Upside: +149.43%
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.48
Upside: +643.24%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.56
Upside: +134.38%
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.00
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $7.00
Upside: +485.71%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $3.17
Upside: +278.55%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $52.52
Upside: +296.04%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $0.67
Upside: +2,277.77%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $8.65
Upside: +940.46%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.90
Upside: +2.56%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $21.04
Upside: -14.45%